Cargando…

A Comparison of Activated Partial Thromboplastin Time and Activated Coagulation Time for Anticoagulation Monitoring during Extracorporeal Membrane Oxygenation Therapy

Background  Unfractionated heparin is used to prevent coagulation activation in patients undergoing extracorporeal membrane oxygenation (ECMO) support. We designed this study to determine the preferable indicator for anticoagulation monitoring. Methods  We conducted a retrospective study and divided...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Ying, Yuan, Zhiyong, Han, Xiaoning, Song, Kai, Xing, Jinyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Georg Thieme Verlag KG 2022
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10281775/
https://www.ncbi.nlm.nih.gov/pubmed/35882351
http://dx.doi.org/10.1055/a-1796-8652
_version_ 1785061060027351040
author Liu, Ying
Yuan, Zhiyong
Han, Xiaoning
Song, Kai
Xing, Jinyan
author_facet Liu, Ying
Yuan, Zhiyong
Han, Xiaoning
Song, Kai
Xing, Jinyan
author_sort Liu, Ying
collection PubMed
description Background  Unfractionated heparin is used to prevent coagulation activation in patients undergoing extracorporeal membrane oxygenation (ECMO) support. We designed this study to determine the preferable indicator for anticoagulation monitoring. Methods  We conducted a retrospective study and divided the patients into an activated coagulation time (ACT)-target group and an activated partial thromboplastin time (aPTT)-target group. The correlations between ACT, aPTT, and the heparin dose were explored. Results  Thirty-six patients were included (19 aPTT-target and 17 ACT-target patients); a total of 555 matched pairs of ACT/aPTT results were obtained. The correlation between the ACT and aPTT measurements was Spearman's Rank Correlation Coefficient ( rs ) = 0.518 in all 555 pairs. The Bland–Altman plot showed data points outside the displayed range (51.2–127.7), suggesting that the agreement between ACT and aPTT was poor. The aPTT group had fewer heparin dose changes (2.12 ± 0.68 vs. 2.57 ± 0.64, p  = 0.05) and a lower cumulative heparin dose (317.6 ± 108.5 vs. 396.3 ± 144.3, p  = 0.00) per day than the ACT group. There was no difference in serious bleeding (9 vs . 5; p  = 0.171) or embolism events (3 vs. 3; p  = 1.0) or in the red blood cell and fresh frozen plasma transfusion volumes between the ACT- and aPTT-target groups. Similarly, there was no significant difference in the ECMO duration (9 [4–15] days vs . 4 [3–14] days; p  = 0.124) or length of ICU hospitalization (17 [5–32] days vs . 13 [4–21] days; p  = 0.451) between the groups. Conclusion  The correlation between ACT and aPTT and the heparin dose was poor. The aPTT group had fewer daily heparin dose changes and a lower cumulative heparin dose per day than the ACT group, with no more bleeding and thrombotic events. Therefore, we recommend aPTT rather than ACT to adjust heparin dose in the absence of better monitoring indicators.
format Online
Article
Text
id pubmed-10281775
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Georg Thieme Verlag KG
record_format MEDLINE/PubMed
spelling pubmed-102817752023-06-21 A Comparison of Activated Partial Thromboplastin Time and Activated Coagulation Time for Anticoagulation Monitoring during Extracorporeal Membrane Oxygenation Therapy Liu, Ying Yuan, Zhiyong Han, Xiaoning Song, Kai Xing, Jinyan Hamostaseologie Background  Unfractionated heparin is used to prevent coagulation activation in patients undergoing extracorporeal membrane oxygenation (ECMO) support. We designed this study to determine the preferable indicator for anticoagulation monitoring. Methods  We conducted a retrospective study and divided the patients into an activated coagulation time (ACT)-target group and an activated partial thromboplastin time (aPTT)-target group. The correlations between ACT, aPTT, and the heparin dose were explored. Results  Thirty-six patients were included (19 aPTT-target and 17 ACT-target patients); a total of 555 matched pairs of ACT/aPTT results were obtained. The correlation between the ACT and aPTT measurements was Spearman's Rank Correlation Coefficient ( rs ) = 0.518 in all 555 pairs. The Bland–Altman plot showed data points outside the displayed range (51.2–127.7), suggesting that the agreement between ACT and aPTT was poor. The aPTT group had fewer heparin dose changes (2.12 ± 0.68 vs. 2.57 ± 0.64, p  = 0.05) and a lower cumulative heparin dose (317.6 ± 108.5 vs. 396.3 ± 144.3, p  = 0.00) per day than the ACT group. There was no difference in serious bleeding (9 vs . 5; p  = 0.171) or embolism events (3 vs. 3; p  = 1.0) or in the red blood cell and fresh frozen plasma transfusion volumes between the ACT- and aPTT-target groups. Similarly, there was no significant difference in the ECMO duration (9 [4–15] days vs . 4 [3–14] days; p  = 0.124) or length of ICU hospitalization (17 [5–32] days vs . 13 [4–21] days; p  = 0.451) between the groups. Conclusion  The correlation between ACT and aPTT and the heparin dose was poor. The aPTT group had fewer daily heparin dose changes and a lower cumulative heparin dose per day than the ACT group, with no more bleeding and thrombotic events. Therefore, we recommend aPTT rather than ACT to adjust heparin dose in the absence of better monitoring indicators. Georg Thieme Verlag KG 2022-07-26 /pmc/articles/PMC10281775/ /pubmed/35882351 http://dx.doi.org/10.1055/a-1796-8652 Text en The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. ( https://creativecommons.org/licenses/by-nc-nd/4.0/ ) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License, which permits unrestricted reproduction and distribution, for non-commercial purposes only; and use and reproduction, but not distribution, of adapted material for non-commercial purposes only, provided the original work is properly cited.
spellingShingle Liu, Ying
Yuan, Zhiyong
Han, Xiaoning
Song, Kai
Xing, Jinyan
A Comparison of Activated Partial Thromboplastin Time and Activated Coagulation Time for Anticoagulation Monitoring during Extracorporeal Membrane Oxygenation Therapy
title A Comparison of Activated Partial Thromboplastin Time and Activated Coagulation Time for Anticoagulation Monitoring during Extracorporeal Membrane Oxygenation Therapy
title_full A Comparison of Activated Partial Thromboplastin Time and Activated Coagulation Time for Anticoagulation Monitoring during Extracorporeal Membrane Oxygenation Therapy
title_fullStr A Comparison of Activated Partial Thromboplastin Time and Activated Coagulation Time for Anticoagulation Monitoring during Extracorporeal Membrane Oxygenation Therapy
title_full_unstemmed A Comparison of Activated Partial Thromboplastin Time and Activated Coagulation Time for Anticoagulation Monitoring during Extracorporeal Membrane Oxygenation Therapy
title_short A Comparison of Activated Partial Thromboplastin Time and Activated Coagulation Time for Anticoagulation Monitoring during Extracorporeal Membrane Oxygenation Therapy
title_sort comparison of activated partial thromboplastin time and activated coagulation time for anticoagulation monitoring during extracorporeal membrane oxygenation therapy
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10281775/
https://www.ncbi.nlm.nih.gov/pubmed/35882351
http://dx.doi.org/10.1055/a-1796-8652
work_keys_str_mv AT liuying acomparisonofactivatedpartialthromboplastintimeandactivatedcoagulationtimeforanticoagulationmonitoringduringextracorporealmembraneoxygenationtherapy
AT yuanzhiyong acomparisonofactivatedpartialthromboplastintimeandactivatedcoagulationtimeforanticoagulationmonitoringduringextracorporealmembraneoxygenationtherapy
AT hanxiaoning acomparisonofactivatedpartialthromboplastintimeandactivatedcoagulationtimeforanticoagulationmonitoringduringextracorporealmembraneoxygenationtherapy
AT songkai acomparisonofactivatedpartialthromboplastintimeandactivatedcoagulationtimeforanticoagulationmonitoringduringextracorporealmembraneoxygenationtherapy
AT xingjinyan acomparisonofactivatedpartialthromboplastintimeandactivatedcoagulationtimeforanticoagulationmonitoringduringextracorporealmembraneoxygenationtherapy
AT liuying comparisonofactivatedpartialthromboplastintimeandactivatedcoagulationtimeforanticoagulationmonitoringduringextracorporealmembraneoxygenationtherapy
AT yuanzhiyong comparisonofactivatedpartialthromboplastintimeandactivatedcoagulationtimeforanticoagulationmonitoringduringextracorporealmembraneoxygenationtherapy
AT hanxiaoning comparisonofactivatedpartialthromboplastintimeandactivatedcoagulationtimeforanticoagulationmonitoringduringextracorporealmembraneoxygenationtherapy
AT songkai comparisonofactivatedpartialthromboplastintimeandactivatedcoagulationtimeforanticoagulationmonitoringduringextracorporealmembraneoxygenationtherapy
AT xingjinyan comparisonofactivatedpartialthromboplastintimeandactivatedcoagulationtimeforanticoagulationmonitoringduringextracorporealmembraneoxygenationtherapy